Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02715947|
Recruitment Status : Unknown
Verified December 2015 by Yijing He, Central South University.
Recruitment status was: Recruiting
First Posted : March 22, 2016
Last Update Posted : March 22, 2016
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis Vulgaris||Drug: Methotrexate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
Other Name: Amethopterin
- disease control rate [ Time Frame: 8 weeks after the first treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715947
|Contact: Yijing He, MD,PhDfirstname.lastname@example.org|
|Xiangya Hospital Central South University||Recruiting|
|Changsha, Hunan, China, 410008|
|Contact: Yijing He, MD, PhD +86-1587481262 email@example.com|
|Principal Investigator:||Xiang Chen, MD||Xiangya Hospital of Central South University|